Tempus AI Business Summary

Tempus AI, Inc. (TEM) operates a dual-engine business model centered on its proprietary "operating system" for precision medicine, generating revenue through high-volume diagnostic testing and high-margin data licensing. The Genomics segment produces revenue via clinical molecular tests (e.g., xT, xF, and xR assays) and hereditary sequencing following the 2025 acquisition of Ambry Genetics, while the Data and Applications segment monetizes one of the world's largest libraries of clinical-genomic data through multi-year licensing agreements, AI-driven insights, and clinical trial matching services for biopharma partners. As of early 2026, the company has achieved non-GAAP profitability and is scaling toward a $1.59 billion annual revenue target. Tempus competes directly with Guardant Health, Exact Sciences, SOPHiA GENETICS, and IQVIA, positioning itself as a vertically integrated platform that uniquely bridges the gap between diagnostic hardware and longitudinal data analytics to accelerate therapeutic discovery. Founded in 2015 by serial entrepreneur Eric Lefkofsky—the co-founder of Groupon, Lightbank, and Pathos AI—Tempus is led by a veteran executive team including Chief Technology Officer Shane Colley, Chief Financial Officer Jim Rogers, and Chief Operating Officer Ryan Fukushima. The leadership is supported by a high-pedigree board of directors featuring former FDA Commissioner Scott Gottlieb, Nobel laureate Jennifer Doudna, and NEA Chairman Peter Barris. The company’s institutional backing remains robust, with significant equity positions held by SoftBank, Google, Baillie Gifford, and major asset managers such as Vanguard and BlackRock, reflecting its status as a cornerstone player in the AI-driven healthcare infrastructure market.